Welcome To Quark

Quark Pharmaceuticals, Inc. is a late-stage pharmaceutical company and a leader in the discovery and development of novel small interfering RNA (siRNA) therapeutics. We aim to improve the lives of millions of patients by harnessing the natural mechanism of siRNAs. By inhibiting key disease-related genes, we can address serious unmet medical needs that could not be dreamed curable before the advent of siRNA therapies.

Quark’s late-stage pipeline includes siRNA therapies for renal protection in cardio-renal disease and neuroprotection in ophthalmology, with two products currently in Phase 3 clinical trials. Late- and early-stage pipeline products address a variety of disease areas with considerable unmet medical needs, targeting different genes with proven delivery to multiple organs. With a cumulative investment of over US$700 million, Quark has generated over 420 issued patents worldwide, of which more than 80 were granted in the US and in Europe.

Incorporated in 1994, Quark is privately held by the SBI Group with headquarters and a drug development team in Newark, California, and a research team at the Weizmann Science Park, Ness Ziona, Israel.